FONT SIZE   S | M | L
Email This Article
Your Name:
Your Email:
Email To:
Comment:
Optional
Authentication:  
1 + 8 = ?: (Required) Please type in the correct answer to the math question.

  
clear
You are sending a link to...
Dr. Carl Awh presents the first report of an implant that may transform the treatment of wet macular degeneration.
Dr. Awh presented the results of the Phase 2 LADDER clinical trial at the 36th Annual Meeting of the American Society of Retina Specialists in Vancouver, BC, Canada on July 25, 2018. Tennessee Retina was a clinical trial site in LADDER, which evaluated a small implant that releases ranibizumab (Lucentis®) into the eye over many months, potentially eliminating the need for monthly eye injections. Click the weblink below for more information about this exciting new treatment. Tennessee Retina has been selected as a site for the final, Phase 3 clinical trial, which will begin later this year.
https://www.medscape.com/viewarticle/899911
sun mon tue wed thu fri sat
   1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31   

"Tennessee Retina is great; There are no words to describe the way Patient & Family are treated with the utmost care, personal treatment. The Doctors that we have contact with & the staff are terrific!!!"

Herma
via Facebook